Clinical Trial Update: Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial comparing NCX 470 to latanoprost in open-angle glaucoma or ocular hypertension completed with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Latanoprost (Latanoprost)
• NCX-470 (NCX-470)

Snippet

Sponsor: Nicox Ophthalmics, Inc. | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2025-05-30